

## **THE CARE GROUP RESEARCH OPPORTUNITIES**

*If you are interested in participating in any of the following research currently conducted by The Care Group, please contact Andy Scroggs at 3`17-338-9380.*

**GE MBG312:** This is an Open-Label, Multicenter, Phase III study to investigate the prognostic usefulness of I123-mIBG imaging to identify those subjects with Heart Failure (class II and III) who will experience an Adverse Cardiac Event; **Mary N. Walsh, M.D. Principal Investigator**

**KING VISION 305:** A Multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled (i.e. adenosine), complete two-arm crossover study with a reference third arm; **MARY N. WALSH, M.D. Principal Investigator**

**DESTINY HF:** A 12 week multicenter, randomized, double-blind, 2-arm parallel treatment regimen, exploratory study to evaluate the tolerability and safety of valsartan administered once daily versus twice daily in patients with stable, chronic heart failure (NYHA Class II-III); **MARY N. WALSH, M.D. Principal Investigator**

**MASCOT:** Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and Cilostazol), for 24-week improvement of walking distance in patients with stage II peripheral arterial disease who benefit from optimal prevention strategy including Clopidogrel; **Elaine K. Moen, M.D. Principal Investigator**

**PROVIDENCE:** A prospective, randomized, double-blind (phase 3) study of Rifalazil treatment on the number of vascular interventions and peripheral vascular disease endpoints in *Chlamydia pneumoniae* seropositive patients; **Elaine K. Moen, M.D. Principal Investigator**

**ATHENA:** A placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter; **Eric N. Prystowsky, M.D. Principal Investigator**

**MADIT-CRT:** Multicenter Automatic Defibrillator Implantation Cardiac Resynchronization Therapy Trial; Bi-V device therapy for pts. with Class I or Class II CHF; **Eric N. Prystowsky, M.D. Principal Investigator**

**REVERSE:** Resynchronization reverses remodeling in systolic left ventricular dysfunction; BI-V device therapy for pts. with Class I or Class II CHF; **Mary N. Walsh, M.D. Principal Investigator**

## **THE CARE GROUP RESEARCH OPPORTUNITIES**

**RELY TRIAL:** Randomized evaluation of long term anticoagulant therapy comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in pts. with non-valvular AF; prospective, multi-center, parallel-group, non-inferiority trial; New anticoagulant drug therapy trial for stroke prevention in atrial fibrillation patients.; Benzy **Padanilam, M.D. Principal Investigator**